Fludeoxyglucose

Summary

Fludeoxyglucose (CHEMBL2068864) is an approved small molecule; indicated across 2 conditions including non-small cell lung carcinoma and colorectal neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 182.15 Da · C6H11FO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2068864
Name	Fludeoxyglucose
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2737302
ChEBI	CHEBI:49126
Molecular formula	C6H11FO5
Molecular weight	182.15
InChIKey	ZCXUVYAZINUVJD-IVMDWMLBSA-N

SMILES: C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)F)O)O)O

IUPAC name: (3R,4S,5S,6R)-3-fluoro-6-(hydroxymethyl)oxane-2,4,5-triol

Also known as: Fludeoxyglucose, FLUDEOXYGLUCOSE

Parent form; salt/anhydrous children: CHEMBL2030434

Patent coverage: 10 distinct patent families (27 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
colorectal neoplasm	2	MONDO:0005335	EFO:0004142

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03937583	PHASE4	UNKNOWN	Screening for Cancer in Patients With Unprovoked VTE
NCT01146054	PHASE2	COMPLETED	Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
NCT02886793	PHASE1/PHASE2	COMPLETED	Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects
NCT01089998	PHASE1	COMPLETED	PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
NCT02759887	Not specified	COMPLETED	Relationship Between Down Syndrome (DS) and Alzheimer’s Disease (AD)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).